Comparative Mortality of Hemodialysis Patients at For-profit and Not-for-profit Dialysis Facilities in the United States, 1998 to 2003: a Retrospective Analysis
Overview
Authors
Affiliations
Background: Concern lingers that dialysis therapy at for-profit (versus not-for-profit) hemodialysis facilities in the United States may be associated with higher mortality, even though 4 of every 5 contemporary dialysis patients receive therapy in such a setting.
Methods: Our primary objective was to compare the mortality hazards of patients initiating hemodialysis at for-profit and not-for-profit centers in the United States between 1998 and 2003. For-profit status of dialysis facilities was determined after subjects received 6 months of dialysis therapy, and mean follow-up was 1.7 years.
Results: Of the study population (N = 205,076), 79.9% were dialyzed in for-profit facilities after 6 months of dialysis therapy. Dialysis at for-profit facilities was associated with higher urea reduction ratios, hemoglobin levels (including levels above 12 and 13 g/dL [120 and 130 g/L]), epoetin doses, and use of intravenous iron, and less use of blood transfusions and lower proportions of patients on the transplant waiting-list (P < 0.05). Patients dialyzed at for-profit and at not-for-profit facilities had similar mortality risks (adjusted hazards ratio 1.02, 95% CI 0.99-1.06, P = 0.143).
Conclusion: While hemodialysis treatment at for-profit and not-for-profit dialysis facilities is associated with different patterns of clinical benchmark achievement, mortality rates are similar.
Liu S, Cheng C, Wu M, Zheng C, Hsu C, Wu M BMJ Open. 2021; 11(9):e045832.
PMID: 34475147 PMC: 8413873. DOI: 10.1136/bmjopen-2020-045832.
Salerno S, Dahlerus C, Messana J, Wisniewski K, Tong L, Hirth R Health Serv Res. 2020; 56(1):123-131.
PMID: 33184854 PMC: 7839641. DOI: 10.1111/1475-6773.13600.
Nie Y, Witten B, Schatell D, Assari S, Ding X, Saran R Clin Kidney J. 2020; 13(3):434-441.
PMID: 32699624 PMC: 7367129. DOI: 10.1093/ckj/sfz077.
Pedrini L, Winter A, Cerino F, Zawada A, Garbelli M, Feuersenger A BMC Nephrol. 2019; 20(1):35.
PMID: 30709341 PMC: 6359808. DOI: 10.1186/s12882-019-1224-2.
Brunelli S, Wilson S, Krishnan M, Nissenson A BMC Nephrol. 2014; 15:121.
PMID: 25047925 PMC: 4113666. DOI: 10.1186/1471-2369-15-121.